MG1 MA3

Drug Profile

MG1 MA3

Alternative Names: Ad MAGEA3; Marabex; MG1 Maraba/MAGE-A3; MG1-MAGEA3; MG1MA3

Latest Information Update: 13 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Children's Hospital of Eastern Ontario; McMaster University; University of Ottawa
  • Developer National Cancer Institute (Canada); Turnstone Biologics
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants; Neoplasm antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 10 Oct 2017 AbbVie enters into an option license agreement with Turnstone Biologics for its oncolytic viral immunotherapies
  • 02 Jun 2017 Preliminary efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 01 Dec 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater) in Canada (IV) (NCT02879760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top